8-K: Pacira BioSciences Secures New $300 Million Revolving Credit Facility, Refinances Existing Debt

Pacira BioSciences, Inc. has entered into a new $300 million senior secured revolving credit facility with Wells Fargo Bank, National Association, to refinance its existing credit agreement and provide ongoing working capital, maturing on July 3, 2030.

Summary

• Pacira BioSciences, Inc. (the "Company") entered into a new Credit Agreement on July 3, 2025, with Wells Fargo Bank, National Association, as administrative agent, and other lenders.
• The new Credit Agreement provides for a senior secured revolving credit facility totaling $300.0 million, including a $10.0 million letter of credit sublimit and a $15.0 million swingline loan sublimit.
• The facility is secured by substantially all of the Company's and its subsidiary guarantors' assets and is scheduled to mature on July 3, 2030.
• The Company used a portion of the new revolving loans to repay and terminate its existing credit agreement, dated March 31, 2023, without incurring any prepayment penalties or fees.
• The Credit Agreement allows for incremental term facilities up to the greater of $225.0 million and 100% of Consolidated EBITDA.
• Interest rates for revolving loans are variable, based on the Company's Senior Secured Net Leverage Ratio, ranging from Base Rate plus 1.50% to 2.25% for ABR borrowings, and SOFR plus 2.50% to 3.25% for Term Benchmark or Daily Simple SOFR borrowings.
• The Company must comply with financial covenants including a maximum Senior Secured Net Leverage Ratio of 3.00 to 1.00, a minimum Fixed Charge Coverage Ratio of 1.50 to 1.00, and a minimum Liquidity of $200.0 million (less 2025 Convertible Notes prepayments) until the 2025 Convertible Notes are fully paid.

Sentiment

Score: 7

Explanation: The document reflects a positive financial management step, securing new financing and refinancing existing debt without penalties, which enhances the company's liquidity and financial flexibility. While it's a routine financial transaction, the favorable terms and extended maturity are beneficial.

Positives

• Secured a new $300 million revolving credit facility, enhancing liquidity and providing ongoing working capital.
• Successfully refinanced the existing credit agreement without incurring any prepayment penalties or fees.
• The new facility has a longer maturity date of July 3, 2030, providing long-term financial stability.
• Ability to add incremental term facilities up to $225.0 million or 100% of Consolidated EBITDA, offering future financing flexibility.

Negatives

• The new credit facility is secured by substantially all of the Company's and its subsidiary guarantors' assets, increasing the secured debt burden.
• The facility includes financial covenants (Senior Secured Net Leverage Ratio, Fixed Charge Coverage Ratio, Minimum Liquidity) that the Company must continuously meet, potentially limiting financial flexibility.

Risks

• Failure to maintain the Senior Secured Net Leverage Ratio at or below 3.00 to 1.00 could trigger an Event of Default.
• Failure to maintain the Fixed Charge Coverage Ratio at or above 1.50 to 1.00 could trigger an Event of Default.
• Failure to maintain Liquidity of at least $200.0 million (less any prepayments of 2025 Convertible Notes) could trigger a Liquidity Default, accelerating the Maturity Date.
• Incurrence of judgments for payment of money exceeding $20,000,000 (if not paid, bonded, or covered by a solvent insurer) could lead to an Event of Default.
• Breaches of Anti-Corruption Laws, Anti-Money Laundering Laws, or Sanctions could result in an Event of Default.
• Material adverse changes in business, assets, operations, or financial condition could lead to an Event of Default.
• Non-compliance with Health Care Laws or loss of Health Care Permits could result in a Material Adverse Effect and potentially an Event of Default.

Future Outlook

The document primarily details the terms of a new credit agreement and the refinancing of existing debt, focusing on financial structure and compliance. It does not provide a general future outlook or specific guidance on business performance beyond the implications of securing new financing for general corporate purposes and working capital.

Management Comments

• Shawn M. Cross, Chief Financial Officer, signed the Credit Agreement on behalf of Pacira BioSciences, Inc.
• Kristen Williams, Chief Administrative Officer and Secretary, signed the Form 8-K on behalf of Pacira BioSciences, Inc.

Industry Context

This announcement is specific to Pacira BioSciences' corporate financing strategy. It reflects a standard practice for publicly traded companies to manage their debt structure and secure liquidity for ongoing operations and strategic initiatives. The terms of the credit facility, including interest rates tied to leverage ratios and financial covenants, are typical for the pharmaceutical and biotechnology industry, which often requires significant capital for R&D, manufacturing, and commercialization.

Comparison to Industry Standards

• The $300 million revolving credit facility is a substantial amount, providing significant liquidity and flexibility, which is common for established biotechnology companies like Pacira BioSciences.
• The interest rate structure, based on SOFR and ABR with spreads tied to the Senior Secured Net Leverage Ratio, aligns with prevailing market practices for corporate credit facilities in the U.S. financial sector.
• The financial covenants, including a maximum Senior Secured Net Leverage Ratio of 3.00 to 1.00 and a minimum Fixed Charge Coverage Ratio of 1.50 to 1.00, are within typical ranges for investment-grade or near-investment-grade companies in the pharmaceutical industry, reflecting a balance between financial flexibility and lender protection.
• The ability to incur incremental term facilities up to 100% of Consolidated EBITDA or $225 million provides a growth-oriented financing option, comparable to facilities offered to companies with M&A or significant R&D pipelines.
• The absence of prepayment penalties on the terminated Existing Credit Agreement is a favorable outcome, indicating efficient debt management and potentially strong negotiation leverage.

Corporate Governance

Legal Proceedings

• The document mentions that fees and settlement expenses associated with disputes or litigation, including patent infringement, up to $10,000,000 per Reference Period, can be added back to Consolidated EBITDA for calculation purposes.
• A judgment for the payment of money in excess of $20,000,000 (if not paid, fully bonded, or covered by a solvent and unaffiliated insurer for 60 consecutive days) against the Company or any Subsidiary would constitute an Event of Default.

Related Party Transactions

• Transactions with Affiliates are permitted under certain conditions, including being on terms not materially less favorable than arms-length transactions, or as specifically set forth on Schedule 6.07 (which is not provided in the excerpt).

Stakeholder Impact

• **Shareholders**: The new credit facility provides financial stability and flexibility for general corporate purposes and potential acquisitions, which could support long-term growth and shareholder value. The financial covenants impose discipline that could protect shareholder interests.
• **Lenders**: The new agreement establishes the terms for the lenders' investment, including interest rates, security interests, and covenants, defining their risk and return profile.
• **Employees**: The facility supports ongoing working capital needs, which indirectly contributes to the stability of employment and operational continuity.
• **Customers/Suppliers**: Stable financing can ensure the Company's ability to maintain operations, develop products, and fulfill obligations to customers and suppliers.
• **Creditors (Existing)**: The refinancing of the Existing Credit Agreement impacts previous creditors by terminating their claims and obligations under that agreement.

Next Steps

• Ongoing compliance with financial covenants (Senior Secured Net Leverage Ratio, Fixed Charge Coverage Ratio, Minimum Liquidity).
• Payment of principal and interest on the new revolving loans as they become due.
• Potential utilization of the letter of credit and swingline loan sublimits for operational needs.
• Possible future requests for incremental term facilities for general corporate purposes or permitted acquisitions.
• Timely delivery of financial statements and other information to the Administrative Agent as required by the agreement.

Key Dates

Keywords

Pacira BioSciences, Credit Agreement, Revolving Credit Facility, Refinancing, SEC Filing, 8-K, Debt, Financial Covenants, Liquidity, Corporate Finance, Biotechnology, Pharmaceuticals, Wells Fargo